PHAS
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
PHAS
Delisted
PHAS was delisted on the 2nd of November, 2022.
38 hedge funds and large institutions have $3.89M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 12 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
less funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less capital invested
Capital invested by funds: $ → $
less first-time investments, than exits
New positions opened: | Existing positions closed:
Holders
38
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$105K | |
| 2 | +$27.2K | |
| 3 | +$13K | |
| 4 |
UBV
United Bank (Virginia)
Vienna,
Virginia
|
+$1.97K |
Top Sellers
| 1 | -$450K | |
| 2 | -$144K | |
| 3 | -$73K | |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$65K |
| 5 |
Stifel Financial
St. Louis,
Missouri
|
-$62K |